![]() |
Market Research Report
Product code
1053761
Sleep Apnea Diagnostics Market by Product (Polysomnography Devices, Actigraphy Systems, Respiratory Polygraph, Sleep Apnea Screening Device, and Oximeter) and End User : Global Opportunity Analysis and Industry Forecast, 2021-2030 |
Sleep Apnea Diagnostics Market by Product (Polysomnography Devices, Actigraphy Systems, Respiratory Polygraph, Sleep Apnea Screening Device, and Oximeter) and End User : Global Opportunity Analysis and Industry Forecast, 2021-2030 |
Published: November 24, 2021
Allied Market Research
Content info: 207 Pages
Delivery time: 2-3 business days
|
The global sleep apnea diagnostics market was valued at $290.50 million in 2020, and is projected to reach $545.09 million by 2030, registering a CAGR of 6.7% from 2021 to 2030.
Obstructive sleep-disordered breathing (SDB) is a syndrome of upper airway dysfunction during sleep that is characterized by snoring and/or increased respiratory effort secondary to greater upper airway resistance and pharyngeal collapsibility. Obstructive sleep apnea (OSA) is a sleep disorder that results in significant decrease or cessation of airflow in the presence of breathing effort. If the brain does not send the signals needed to breathe, the condition is referred to as central sleep apnea. Around 85-90% of OSA patients are estimated to remain undiagnosed that demonstrates the unmet medical needs. Sleep apnea diagnostic products evaluate the breathing and other body functions of patients during sleep, thereby boosting the demand for these devices to combat sleep apnea disease. The general characteristic of Obstructive Sleep Apnea is the increased collapsibility of the upper airway during sleep resulting in markedly reduced (hypopnea) or absent (apnea) airflow at the nose and/or mouth which is usually accompanied by oxyhemoglobin desaturation and is typically terminated by a brief micro-arousal. Repeated episodes of apnea lead to a sustained reduction in oxyhemoglobin saturation and sleep fragmentation with diminished amounts of slow-wave and rapid eye movement (REM) sleep. The major predisposing factor for sleep apnea is excess body weight. It has been estimated that 58% of moderate to severe OSA is attributable to obesity.
The global sleep apnea diagnostic market is anticipated to register notable growth due to increase in geriatric population as well as a surge in prevalence of sedentary lifestyle disorders such as obesity and diabetes, as well as considerable increase in awareness about sleep apnea. Furthermore, technical developments to make products more convenient for users as well as a notable increase in sleep apnea diseases are driving market expansion. However, the market is expected to be hampered by the high cost of sleep apnea treatment tools, restricted reimbursement for these devices, and low patient compliance. On the contrary, the progressive rise in popularity of home healthcare equipment is expected to provide attractive development opportunities for the global market in the near future.
The global sleep apnea diagnostics market is segmented into product, end user, and region. Depending on product, the market is fragmented into polysomnography (PSG) devices, actigraphy systems, respiratory polygraph, sleep apnea screening device, oximeter, and others. On the basis of end user, it is bifurcated into sleep laboratory & hospital and home healthcare. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Coronavirus (COVID-19) was discovered in late December in Hubei province of Wuhan city in China. The disease is caused by a virus, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted from humans to humans. supply chains were disrupted due to restrictions on trade of pharmaceutical ingredients and products across countries. The outbreak of COVID-19 has disrupted workflows in the healthcare sector around the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of healthcare. In the initial days of the COVID-19 pandemic 2020, some countries were in lockdown. They banned trade with other nations and enforced travel restrictions, resulting in decline in diagnostics and surgical procedures in the first half of 2020. In addition, COVID 19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty in breathing. In its disruption to clinical trials and drug supply to patients, the COVID-19 pandemic has impacted the most crucial areas of the sleep apnea diagnostics market. The banned trade with other nations and enforced travel restrictions, resulting in decline in diagnostics and surgical procedures in the first half of 2020. According to the study published in the British Journal of Surgery, around 28.4 million elective procedures were cancelled or postponed in May 2020, based on a 12-week period of peak disruption to hospital services due to COVID-19. There has been a significant reduction in hospitals and sleep laboratory-based diagnosis of sleep apnea. Overall impact of the COVID-19 pandemic on the global sleep apnea market was recorded to be negative, owing to the factors such as sleep lab were closed due to lockdown in many countries. However, this situation is expected to change post COVID-19 pandemic in the coming years.
BY PRODUCT
BY END USER
By REGION